53967-81-0

Basic information

• Product Name: 4,6-DICHLORO-5-ETHYLPYRIMIDINE
• Synonyms: 4,6-DICHLORO-5-ETHYLPYRIMIDINE
• CAS NO: 53967-81-0
• Molecular Formula: C₆H₆Cl₂N₂
• Molecular Weight: 177.03
• Mol File: 53967-81-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 243.2±35.0 °C(Predicted)
• Appearance: /
• Density: 1.335±0.06 g/cm3(Predicted)
• PKA: -3.96±0.26(Predicted)
• CAS DataBase Reference: 4,6-DICHLORO-5-ETHYLPYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-DICHLORO-5-ETHYLPYRIMIDINE(53967-81-0)
• EPA Substance Registry System: 4,6-DICHLORO-5-ETHYLPYRIMIDINE(53967-81-0)

Safety Data

• Hazardous Substances Data: 53967-81-0(Hazardous Substances Data)

Upstream product

• 26717-67-9 dimethyl ethylmalonate 
• 6082-49-1 ethyl propanediamide 
• 3603-15-4 5-ethylpyrimidine-4,6-diol 
• 75-44-5 phosgene 
• 109-74-0 propyl cyanide 
• 77287-34-4 formamide 

Downstream Products

• 1428249-60-8 5-ethyl-6-(4-(4-(4-fluoro-3-(trifluoromethyl)phenyl)-1-(2-(3-fluoroazetidin-1-yl)ethyl)-1H-imidazol-2-yl)piperidin-1-yl)pyrimidin-4-amine 
• 1380066-07-8 5-ethyl-N-(2-hydroxy-5-trifluoromethyl-phenyl)-pyrimidine-4-carboxamide 

Relevant articles and documents

COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS

Provided herein is a compound of formula (XXXII) or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer thereof or a physiologically functional derivative thereof, wherein R1, R2, R3, G, A, E, n, p, and q are defined herein. Also provided herein are compositions comprising a compound of formula (XXXII), and methods of using a compound of formula (XXXII), e.g., in the treatment or prevention of skin disorders.

Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same

A subject of the invention is the compounds of formula (I): in which R1, R2, R3, R4 and G have the meanings indicated in the description, their preparation process, their use as medicaments having an antagonist activity on the vitronectin receptor and the pharmaceutical compositions containing them.